Utrecht, The Netherlands / Cambridge, UK - 30 November 2006 - PanGenetics B.V. announced today that the Company has successfully concluded a licensing agreement with Schering-Plough Corporation. Under the terms of the agreement, Schering-Plough has granted PanGenetics exclusive rights to an undisclosed therapeutic antibody from Schering-Plough’s preclinical portfolio.
